

## Accepted Manuscript

Title: Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

Author: David E. Gerber David A. Boothman Farjana J Fattah  
Ying Dong Hong Zhu Rachel A. Skelton Laurin L. Priddy  
Peggy Vo Jonathan E. Dowell Venetia Sarode Richard Leff  
Claudia Meek Yang Xie Joan H. Schiller

PII: S0169-5002(15)30077-5  
DOI: <http://dx.doi.org/doi:10.1016/j.lungcan.2015.10.008>  
Reference: LUNG 4960

To appear in: *Lung Cancer*

Received date: 21-7-2015  
Revised date: 22-9-2015  
Accepted date: 4-10-2015

Please cite this article as: Gerber David E, Boothman David A, Fattah Farjana J, Dong Ying, Zhu Hong, Skelton Rachel A, Priddy Laurin L, Vo Peggy, Dowell Jonathan E, Sarode Venetia, Leff Richard, Meek Claudia, Xie Yang, Schiller Joan H. Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. *Lung Cancer* <http://dx.doi.org/10.1016/j.lungcan.2015.10.008>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

David E. Gerber<sup>a,c,\*</sup>, David A. Boothman<sup>b,e</sup>, Farjana JFattah<sup>c</sup>, Ying Dong<sup>c</sup>, Hong Zhu<sup>c,e</sup>, Rachel A. Skelton<sup>c</sup>, Laurin L. Priddy<sup>c</sup>, Peggy Vo<sup>c</sup>, Jonathan E. Dowell<sup>a,e</sup>, Venetia Sarode<sup>d</sup>, Richard Leff<sup>6</sup>, Claudia Meek<sup>f</sup>, Yang Xie<sup>c,e</sup>, Joan H. Schiller<sup>a,e</sup>

<sup>a</sup>Department of Internal Medicine (Division of Hematology-Oncology), <sup>b</sup>Department of Pharmacology, <sup>c</sup>Department of Clinical Sciences (Biostatistics), <sup>d</sup>Department of Pathology, and <sup>e</sup>Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center. <sup>f</sup>Texas Tech University Health Sciences Center School of Pharmacy.

## \* Corresponding Author:

David E. Gerber, MD  
Division of Hematology-Oncology  
Harold C. Simmons Cancer Center  
University of Texas Southwestern Medical Center  
5323 Harry Hines Blvd.  
Mail Code 8852  
Dallas, Texas 75390-8852  
Phone: 214-648-4180  
Fax: 214-648-1955  
E-mail: [david.gerber@utsouthwestern.edu](mailto:david.gerber@utsouthwestern.edu)

Download English Version:

<https://daneshyari.com/en/article/8454887>

Download Persian Version:

<https://daneshyari.com/article/8454887>

[Daneshyari.com](https://daneshyari.com)